Walt R P
Department of Medicine, Birmingham University, UK.
Methods Find Exp Clin Pharmacol. 1989;11 Suppl 1:97-9.
The first H2-receptor antagonist, cimetidine, has been succeeded by ranitidine, and more recently nizatidine and famotidine. Others will doubtless follow. The pharmacodynamic differences between cimetidine and ranitidine, in terms of potency, are not obviously translated into therapeutic differences. Some studies have shown that the increased potency of standard doses of ranitidine affords an advantage, in terms of ulcer healing and relapse, over cimetidine. The therapeutic effects of these drugs can be predicted from their pharmacodynamic profiles and in the doses recommended differences between the newest agents and ranitidine would not be expected. It is, thus, difficult to define a specific clinical role for the newer drugs on the grounds of efficacy. Their importance may relate to the provision of encouragement for future drug development.
第一代H2受体拮抗剂西咪替丁已被雷尼替丁所取代，最近又有了尼扎替丁和法莫替丁。无疑还会有其他药物相继出现。西咪替丁和雷尼替丁在药效方面的差异，在效力上并未明显转化为治疗差异。一些研究表明，标准剂量雷尼替丁效力的提高，在溃疡愈合和复发方面比西咪替丁具有优势。这些药物的治疗效果可以从其药效学特征预测，按照推荐剂量，预计最新药物与雷尼替丁之间不会有差异。因此，很难根据疗效来界定这些新药的具体临床作用。它们的重要性可能在于为未来药物研发提供了激励。
